ASCO26: Toni Choueiri, MD, KEYNOTE-654

Data highlights limitations of ctDNA assay used to predict outcomes in participants with renal cell carcinoma treated with adjuvant pembrolizumab in the KEYNOTE-564 trial. Dana-Farber Cancer Institute's Dr. Toni Choueiri explains that ctDNA+ was associated with worse disease-free outcomes, but sensitivity was low.

July 1, 2026

Dana-Farber

1

The ctDNA assay used in the KEYNOTE-564 trial has limitations in predicting outcomes for renal cell carcinoma.
2

Dr. Toni Choueiri from Dana-Farber Cancer Institute discussed the association of ctDNA+ with worse disease-free outcomes.
3

The sensitivity of the ctDNA assay in predicting outcomes was found to be low.
4

Participants in the KEYNOTE-564 trial were treated with adjuvant pembrolizumab.
5

The findings highlight the challenges in using ctDNA as a biomarker for renal cell carcinoma outcomes.

ASCO26: Toni Choueiri, MD, KEYNOTE-654

1

2

3

4

5

Original Source(s)

ASCO26: Toni Choueiri, MD, KEYNOTE-654

Related Content

Computed tomography guided microwave ablation for the treatment of clinical T1a renal cell carcinoma: a comparison to robot-assisted laparoscopic partial nephrectomy

Evaluating the Prognostic Nutritional Index in Renal Cell Carcinoma Patients: A Comprehensive Systematic Review and Meta-Analysis Update

Combination Immunotherapy Approaches in Metastatic Renal Cell Carcinoma with Favorable Risk Scores: A Meta-Analysis of Individual Patient Data